We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals
Read MoreHide Full Article
Shares of Zymeworks (ZYME - Free Report) were up 15.86% on Oct 19 after the company announced a licensing deal with Jazz Pharmaceuticals (JAZZ - Free Report) for the former’s HER-2 targeted bispecific antibody, zanidatamab.
However, Zymeworks’ stock has declined 60.3% in the year-to-date period compared with the industry’s fall of 24.1%.
Image Source: Zacks Investment Research
Pursuant to the deal, Jazz will acquire the rights to develop and commercialize zanidatamab across all its indications in all territories, except in Asia Pacific territories, where the drug is already licensed to BeiGene (BGNE - Free Report) .
Zymeworks entered into a strategic collaboration with BeiGene in 2018, where the latter acquired the exclusive rights to develop and commercialize Zymeworks’ bispecific candidates zanidatamab and its second product candidate zanidatamab zovodotin (ZW49) in Asia (excluding Japan), Australia and New Zealand.
Under the terms of the Zymeworks-Jazz agreement, Jazz will make an upfront payment of $50 million to Zymeworks, once the necessary regulatory bodies approve the transaction.
Additionally, after Zymeworks reports the data from the pivotal HERIZON-BTC- study evaluating zanidatamab as a monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancer (BTC), Jazz can choose to continue with the collaboration. In case Jazz decides to continue, it will have to pay an additional $325 million to Zymeworks for the same.
Zymeworks will also be eligible to receive regulatory milestone payments of up to $525 million and up to $862.5 million on achievement of certain commercial milestones. Jazz will also be paying Zymeworks tiered royalties between 10% to 20% of the net sales if and when zanidatamab is approved and marketed. Thus, the deal has the potential to reach a total valuation of $1.76 billion, which impressed investors.
Investors must note that apart from zanidatamab, Zymeworks is also developing zanidatamab zovodotin (ZW49) for a range of HER-2 expressing cancers. The candidate is currently undergoing a phase I study to establish its safety and antitumor activity in humans.
Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has also narrowed down from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for ACAD is 6.83%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals
Shares of Zymeworks (ZYME - Free Report) were up 15.86% on Oct 19 after the company announced a licensing deal with Jazz Pharmaceuticals (JAZZ - Free Report) for the former’s HER-2 targeted bispecific antibody, zanidatamab.
However, Zymeworks’ stock has declined 60.3% in the year-to-date period compared with the industry’s fall of 24.1%.
Image Source: Zacks Investment Research
Pursuant to the deal, Jazz will acquire the rights to develop and commercialize zanidatamab across all its indications in all territories, except in Asia Pacific territories, where the drug is already licensed to BeiGene (BGNE - Free Report) .
Zymeworks entered into a strategic collaboration with BeiGene in 2018, where the latter acquired the exclusive rights to develop and commercialize Zymeworks’ bispecific candidates zanidatamab and its second product candidate zanidatamab zovodotin (ZW49) in Asia (excluding Japan), Australia and New Zealand.
Under the terms of the Zymeworks-Jazz agreement, Jazz will make an upfront payment of $50 million to Zymeworks, once the necessary regulatory bodies approve the transaction.
Additionally, after Zymeworks reports the data from the pivotal HERIZON-BTC- study evaluating zanidatamab as a monotherapy in patients with previously treated advanced or metastatic HER2-amplified biliary tract cancer (BTC), Jazz can choose to continue with the collaboration. In case Jazz decides to continue, it will have to pay an additional $325 million to Zymeworks for the same.
Zymeworks will also be eligible to receive regulatory milestone payments of up to $525 million and up to $862.5 million on achievement of certain commercial milestones. Jazz will also be paying Zymeworks tiered royalties between 10% to 20% of the net sales if and when zanidatamab is approved and marketed. Thus, the deal has the potential to reach a total valuation of $1.76 billion, which impressed investors.
Investors must note that apart from zanidatamab, Zymeworks is also developing zanidatamab zovodotin (ZW49) for a range of HER-2 expressing cancers. The candidate is currently undergoing a phase I study to establish its safety and antitumor activity in humans.
Zymeworks Inc. Price
Zymeworks Inc. price | Zymeworks Inc. Quote
Zacks Rank and A Key Pick
Zymeworks currently has a Zacks Rank #3 (Hold).
A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals (ACAD - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. The loss per share for 2023 has also narrowed down from 67 cents to 60 cents in the same time frame.
Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. The average negative earnings surprise for ACAD is 6.83%.